
Sign up to save your podcasts
Or


Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.
By American College of Cardiology4.2
162162 ratings
Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.

138 Listeners

319 Listeners

503 Listeners

897 Listeners

20 Listeners

30 Listeners

3,383 Listeners

136 Listeners

1,150 Listeners

63 Listeners

39 Listeners

197 Listeners

92 Listeners

377 Listeners

435 Listeners